Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suvecaltamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I known ✓ | Q9P0X4 | 6/20 | 1.00 |
| ▸ | CACNA1H known ✓ | O95180 | 6/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 4/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suvecaltamide SCHEMBL29791943 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL1065999 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1064366 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231799 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1058794 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231358 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060457 | 0.90 | CACNA1I (0.82) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060490 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062188 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062749 | 0.89 | CNR2 (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2025-10-09 | — | — | US | disclosed |
| JP-2024102139-A | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | カビオン・インコーポレイテッド | 2024-07-30 | — | — | JP | disclosed |
| EP-4346817-A1 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251812-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-114760998-A | Methods and materials for treating neurotoxicity | 卡维昂公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3860571-A4 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | Cavion, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220016095-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2022-01-20 | — | — | US | disclosed |
| EP-3860571-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | Cavion, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860571-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | Cavion, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113164393-A | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide | 卡维昂公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164393-A | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide | 卡维昂公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021067697-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | CAVION, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067697-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | CAVION, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020072773-A9 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020072773-A9 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020072773-A9 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020072773-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072773-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-20220016095-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.